Palantir’s Run Feels Unstoppable, But for How Long?
Palantir Technologies (NYSE: PLTR), the data analytics powerhouse, has been one of Wall Street’s most explosive success stories. Since its direct listing in late 2020 at $10 a share, the stock has soared by almost 18-fold gain. Over that same stretch, the S&P 500 hasn’t even doubled.
That kind of outperformance doesn’t happen by accident.
» Read more about: Palantir’s Run Feels Unstoppable, But for How Long? »
Read More
Is Palantir on the Precipice of a Sharp Fall?
Palantir (NYSE:PLTR) has been among the biggest beneficiaries of this year’s AI bull run and the more recent post-election rally. The stock started this year at just $16.58 and has since skyrocketed to over $60 per share.
The last month has been particularly dramatic when PLTR started November a little over $40 before being pushed skyward following election news that was deemed positive and a stellar Q3 earnings report.
» Read more about: Is Palantir on the Precipice of a Sharp Fall? »
Read More
Will Trump’s Energy Secretary Pick Drive Oklo Higher?
Oklo (NYSE: OKLO) shares surged over 18% Monday after President-elect Donald Trump named Liberty Energy CEO Chris Wright as his pick for Energy Secretary.
For Oklo investors, the selection carries special significance – Wright currently serves on Oklo’s board of directors, potentially giving the nuclear innovation company an influential ally in Washington just as it hits its stride with commercial deployments and new acquisitions.
» Read more about: Will Trump’s Energy Secretary Pick Drive Oklo Higher? »
Read More
1 Organ Transplant Disruptor to Buy on the Dip
TransMedics (NASDAQ:TMDX) is an innovative biotechnology company that may well have the potential to disrupt the $11 billion organ transplant industry.
The company’s unique organ care system technology protects and monitors donor organs before they are transplanted into patients, resulting in improved organ health and outcomes. TransMedics also provides logistical services,
» Read more about: 1 Organ Transplant Disruptor to Buy on the Dip »
Read More
1 Signal That Dutch Bros Could Be a Monster Stock
If you gave up on Dutch Bros after its post-IPO slump, you might be kicking yourself right now. After going public in 2021 and fizzling out soon after, Dutch Bros has staged a remarkable comeback, rising nearly 90% over the past 2 years.
And this rebound isn’t just a flash in the pan.
» Read more about: 1 Signal That Dutch Bros Could Be a Monster Stock »
Read MoreThe Ivy
IBM’s Quantum Breakthrough Could Be a Turning Point
IBM has been tinkering with quantum computing longer than most of today’s retail investors have even been in the market. For decades, the company’s message has been quantum is coming, and when it arrives, it will change everything from chemistry to finance. The problem? The finish line has always felt just out of reach, perpetually ten years away.
» Read more about: IBM’s Quantum Breakthrough Could Be a Turning Point »
Read MoreThe Spotlight
Brinker Just Flashed Classic Reversal Signal, Time to Take a Bite?
After weeks of sluggish price action, Brinker International (NYSE: EAT) is starting to show signs that the bulls are back in the kitchen.
On March 25th, EAT delivered a textbook technical setup that a technical trader could only but describe as a “character change.”
The stock filled a prior gap from early March,
» Read more about: Brinker Just Flashed Classic Reversal Signal, Time to Take a Bite? »
Read MoreThe Daily
Warren Buffett to step down as Berkshire Hathaway CEO after 6 decades
OMAHA, Neb. (WOWT) – Next week Warren Buffett steps down as CEO of Berkshire Hathaway, a role he’s held for six decades. He dropped the retirement bombshell this spring at the annual shareholders meeting.
While Greg Abel will take over operations on Jan. 1 and lead next year’s shareholders meeting, Buffett has said he will still come to the office.
» Read more about: Warren Buffett to step down as Berkshire Hathaway CEO after 6 decades »